Related Experiment Videos
Mechanisms of antineoplastic action of somatostatin analogs
1Department of Medicine, Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada. MD49@MUSICA.MCGILL.CA
Abstract:
Over the past decade, impressive antineoplastic activity of somatostatin analogs has been demonstrated in many tumor models. More recent research has provided information regarding mechanisms underlying the antiproliferative and apoptosis-inducing actions of these compounds. These include both 'direct' mechanisms that are sequellae of binding of somatostatin analogs to somatostatin receptors present on neoplastic cells and 'indirect' mechanisms related to effects of somatostatin analogs on the host. The upregulation of intracellular tyrosine phosphatase activity triggered by binding of ligands to the type II somatostatin receptor has received considerable attention as a direct mechanism, not only because this activity is the converse of the tyrosine kinase activity associated with many peptide mitogen receptors, but also because the type II somatostatin receptor is frequently expressed by common human neoplasms, including breast cancer. The potential importance of indirect mechanisms of action of somatostatin analogs, such as alterations in host insulin-like growth factor physiology, is emphasized by the in vivo antineoplastic activity of these compounds against somatostatin receptor-negative neoplasms. Clinical efficacy and a favorable toxicity profile of somatostatin analogs in the treatment of relatively uncommon conditions such as acromegaly and neuroendocrine tumors have already been demonstrated. Preclinical data now are sufficient to justify controlled clinical trials in breast, prostate, and pancreatic cancer. The development of monthly depot formulations will facilitate the clinical evaluation of somatostatin analogs for these and other indications.
Insights
Somatostatin analogs show significant anticancer effects through direct and indirect mechanisms. Clinical trials are warranted for breast, prostate, and pancreatic cancers, with new formulations aiding evaluation.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Somatostatin analogs exhibit notable antineoplastic activity in various tumor models.
- Mechanisms involve direct receptor binding and indirect host-related effects.
- Type II somatostatin receptor activation upregulates tyrosine phosphatase, counteracting tyrosine kinase activity common in cancers.
Purpose of the Study:
- To elucidate the antiproliferative and apoptosis-inducing mechanisms of somatostatin analogs.
- To evaluate the potential of somatostatin analogs in treating common human neoplasms.
- To support clinical trials for somatostatin analogs in major cancers.
Main Methods:
- Review of preclinical data on somatostatin analog mechanisms of action.
- Analysis of somatostatin receptor expression in human neoplasms.
- Evaluation of in vivo antineoplastic activity, including against receptor-negative tumors.
Main Results:
- Direct mechanisms involve somatostatin receptor binding, notably type II, leading to tyrosine phosphatase activation.
- Indirect mechanisms, such as modulating insulin-like growth factor physiology, contribute to efficacy.
- Efficacy demonstrated against somatostatin receptor-negative tumors highlights indirect pathway importance.
Conclusions:
- Somatostatin analogs possess dual direct and indirect anticancer mechanisms.
- Preclinical evidence supports clinical trials for breast, prostate, and pancreatic cancers.
- Monthly depot formulations will enhance clinical evaluation and therapeutic application.